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Objective: To investigate demographic, socioeconomic, lifestyle, and medical factors that might predispose
women to cervical human papillomavirus (HPV) infection. Method: A cross-sectional population-based
study was performed. Women aged 18–64 years who attended selected obstetrics and gynecology or sexual-
ly transmitted disease (STD) clinics in mainland Portugal between February 2008 and March 2009 were
recruited, according to an age-stratiﬁed sampling strategy. Liquid-based cytology samples were analyzed
centrally for HPV genotype and for cytologic features. Univariate and multivariate logistic regression analyses
identiﬁed risk factors for HPV infection. Results: Among the 2326 women evaluated, the crude prevalence of
HPV infection was 19.4%. Lifetime number of sexual partners was a strong predictor of HPV infection (odds
ratio 5.44 for 5–10 partners versus 1 partner; Pb0.001). Other risk factors were young age (particularly
among women aged 20–24 years; Pb0.001); country of birth other than mainland Portugal (P=0.002);
education up to secondary school level (P=0.010); smoking history (≤10 years; P=0.004); and any STD
in the past 12 months (P=0.052). Conclusion: Data from the present study may aid identiﬁcation of
women at increased risk of HPV infection and target prevention strategies.
Trial registration: National Commission of Data Protection (CNPD) registration number 5346/2007;
Sanoﬁ Pasteur MSD study number HPV-E05.
© 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved., Avenida Padre Cruz, 1649-016
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Infection with human papillomavirus (HPV) is an obligatory event
for the development of cervical cancer [1]. Speciﬁc HPV genotypes
(HPV 6, 11, 16, and 18) are responsible for the majority of anogenital
diseases caused by this virus among women [2,3].
Infection with high-risk HPV genotypes (HPV 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, and 59) in the presence of risk factors that promote
the persistence of infection precedes the development of precancer-
ous lesions of the cervix. These risk factors are either biological,
such as co-infections with other sexually transmitted diseases
(STDs), or behavioral, such as sexual habits. A consistent association
has been demonstrated between an increased lifetime number of
sexual partners and HPV infection among women [4–6]. However, a
number of other factors, such as young age at ﬁrst sexual intercourse,
use of oral contraceptives, and smoking have shown inconsistent
associations with HPV infection [6–9].
The CLEOPATRE (Cervical LEsions Observed by PApillomavirus
Types – a Research in Europe) studies aim to provide a better under-
standing of the epidemiology of HPV infection across Europe. Based
on data for a sample of women attending gynecology/obstetrics orPublished by Elsevier Ireland Ltd. All rights reserved.
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age-stratiﬁed and type-speciﬁc prevalence of cervical HPV infection
in women aged 18–64 years living in mainland Portugal [10]. The ob-
jective of the present analysis was to assess demographic, socioeco-
nomic, lifestyle, and medical factors that may predispose women
enrolled in the CLEOPATRE Portugal study to cervical HPV infection.
2. Materials and methods
The CLEOPATRE Portugal study was a population-based, observa-
tional, cross-sectional study conducted between February 1, 2008,
and March 31, 2009, across the 5 Regional Health Administrations
of mainland Portugal. The study methods have been described in de-
tail previously [10]. Brieﬂy, women aged 18–64 years attending se-
lected obstetrics and gynecology or STD clinics and who had not
been vaccinated against HPV were invited to participate in the
study. Pregnant women for whom a Papanicolaou test was not con-
traindicated were eligible to participate. Virgins and women with a
history of abnormal cytology in the 12 months before the enrolment
visit, who had undergone a hysterectomy and or who had undergone
a cone excision or loop electrosurgical excision procedure in the
24 months before the enrolment visit, were excluded from participa-
tion. The protocol was approved by the National Institute of Health
(INSA), which was the public entity responsible for the present epide-
miologic study. Study procedures were approved by the Ethics Com-
mittee of each collaborating Center. All participants were informed
about the procedures and data handling, and a signed consent form
was obtained prior to any study procedure.
After enrollment, demographic, socioeconomic, lifestyle, and med-
ical details were collected and recorded in a case report form. Liquid-
based cytology samples were collected during a gynecologic exami-
nation and sent to a centralized laboratory for HPV genotyping and
cytologic evaluation. Genotyping was performed using the CLART
HPV 2 assay (GENOMICA, Madrid, Spain). This methodology uses bio-
tinylated primers that amplify a fragment of 450 bp within the HPV
L1 ORF region. Co-ampliﬁcation of an 892-bp region of the CFTR
gene and a 1202-bp fragment of a transformed plasmid provides a
control to ensure DNA adequacy and PCR efﬁciency. Amplicons are
detected by hybridization in a low-density microarray containing
triplicate DNA probes speciﬁc to 35 genotypes (HPV 6, 11, 16, 18,
26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62,
66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 and 89). Semi-quantitative
results can be obtained in an automatic reader. DNA was isolated
from 1 mL of cellular suspension using the NucliSENS easyMAG
(BioMerieux, Boxtel, The Netherlands) system, as speciﬁed in the
manufacturer's instructions. Cytologic evaluation was performed
on the liquid-based samples using the ThinPrep method (Cytyc,
Boxborough, MA, USA), and cytology slides were classiﬁed according
to the Bethesda System.
Statistical analyses were undertaken at the Department of Epide-
miology of INSA using Basic and Complex Samples from SPSS version
17.0 (IBM, Armonk, NY, USA), as described previously [10]. Univariate
logistic regression analysis was conducted to evaluate the association
between HPV infection (dependent variable) and potential risk
factors (explanatory variables). The potential risk factors evaluated
were age; country of birth; level of education; smoking habits; age
at ﬁrst sexual intercourse; contraceptive use; lifetime number of
sexual partners; any circumcised sexual partner; history of cervical
intraepithelial neoplasia; any STD in the past 12 months; and
current status of the immune system. The relative risk estimation
(odds ratio [OR] with 95% conﬁdence interval [CI]) is presented for
each explanatory variable.
The multivariate logistic regression model (Pearson χ2 test)
between HPV infection and the explanatory variables was adjusted
for the variables used in the study design (age group and Regional
Health Administration) and for the variables identiﬁed as statisticallysigniﬁcant (Pb0.05) in the univariate analysis. Using a “forward
conditional” method [11], explanatory variables demonstrating
statistical signiﬁcance in the univariate analyses were entered in
sequence into the multivariate regression equation. A P value of
less than 0.05 was considered statistically signiﬁcant.
3. Results
A total of 2372 womenwere invited to participate in the study and
provided informed consent. One woman was withdrawn by one of
the study investigators, and 45 women were excluded on the basis
of the deﬁned exclusion criteria. In all, 2326 women were included
in the analysis; the mean age of the study group was 32.6±
14.1 years, while the median age was 27 years. The majority of
women were born in Portugal (n=2210; 95.0%); 800 (34.4%) had a
university or college education; and 518 (22.3%) were smokers.
Over half of the study population had children (n=1277; 54.9%)
and 2072 (89.1%) reported using contraception. Most women
reported a single lifetime sexual partner (n=1333; 57.3%); 2246
(96.6%) reported the absence of any STD in the past 12 months;
2234 (96.0%) had no history of cervical intraepithelial neoplasia;
and 2277 (97.9%) were not currently immunocompromised.
The overall prevalence of HPV in the study sample was previously
reported as 19.4% (n=451; 95% CI 17.8–21.0) [10]. Prevalence by age
group ranged from 28.8% (199/691) among women aged 20–24 years
to 5.6% (11/196) among those aged 60–64 years. High-risk HPV geno-
types were identiﬁed in 76.5% (345/451) of the HPV-positive women,
with the highest prevalence among the younger age groups
(18–29 years) [10]. Infection with multiple HPV genotypes was
observed in 7.1% (165/2326) of the study population and 36.6%
(165/451) of the HPV-positive women [10].
The results of the univariate logistic regression analysis of HPV
infection status versus demographic, socioeconomic, lifestyle, and
medical variables is shown in Table 1. Young age increased the risk
of HPV infection, with the highest risk occurring in the 20–24 years
age group. Compared with the 60–64 years age group, the OR was
6.80 (95% CI, 0.87–3.90). Women born outside mainland Portugal
also had an increased risk of HPV infection, as did women educated
up to secondary school level.
Smoking was associated with an increased risk of HPV infection,
with an OR of 2.18 (95% CI, 1.73–2.75), while ex-smokers had a
marginally increased risk (OR 1.13; 95% CI, 0.80–1.59), although this
ﬁnding was not statistically signiﬁcant. Among current smokers, the
risk of HPV infection increased with the number of cigarettes smoked.
However, compared with womenwho had smoked for up to 10 years,
women who had smoked for longer (11–20 years and≥21 years) had
a lower risk of HPV infection. Young age at ﬁrst sexual intercourse and
a high lifetime number of sexual partners were both strongly associ-
ated with the prevalence of HPV infection. Use of contraception in-
creased the risk of HPV infection (OR 2.12; 95% CI, 1.40–3.20) as did
having a circumcised sexual partner (OR 1.72, 95% CI 1.27–2.34).
Women without STDs in the past 12 months had a lower risk of
HPV infection; the OR was 0.31 (95% CI, 0.18–0.53).
The association between age and HPV infection remained statisti-
cally signiﬁcant in the multivariate logistic regression analysis
(Table 2). The highest risk of HPV infection was observed among
women aged 20–24 years, whose risk of infection was 3-fold higher
than that of women aged 60–64 years. The OR for this association
was 3.02 (95% CI, 1.52–6.00; P=0.002). Women born outside main-
land Portugal showed a 2-fold higher risk of infection, with an OR of
2.00 (95% CI, 1.30–3.06; P=0.002). Women educated up to basic or
secondary school level continued to show an increased risk of HPV in-
fection compared with women with a college or university education.
The OR in the 12th year was 1.47 (95% CI, 1.11–1.95; P=0.007), while
the OR in the 9th year was 1.57 (95% CI, 1.16–2.13, P=0.004). Simi-
larly, women smoking for longer than 10 years continued to show a
Table 1
Univariate logistic regression analysis between HPV infection and the explanatory variables.
Explanatory variable No. of participants HPV positive (any genotype) a OR (95% CI) b P value
Age, y 2326 b0.001
60–64 196 11 (5.6) 1.00
50–59 228 13 (5.7) 1.02 (3.20–12.09)
40–49 223 22 (9.9) 1.84 (3.62–12.77)
30–39 256 32 (12.5) 2.40 (2.46–8.98)
25–29 458 100 (21.8) 4.70 (1.18–4.90)
20–24 691 199 (28.8) 6.80 (0.87–3.90)
18–19 274 74 (27.0) 6.22 (0.45–2.32)
Country of birth 2326 b0.001
Portugal 2210 400 (18.1) 1.00
Other 116 51 (44.0) 3.55 (2.42–5.20)
Level of education 2323 b0.001
University/college 800 144 (18.0) 1.00
Secondary school (10th–12th year) 587 155 (26.4) 1.64 (1.26–2.11)
Basic school (5th–9th year) 500 119 (23.8) 1.42 (1.08–1.87)
Primary school (1st–4th year) 351 30 (8.5) 0.43 (0.28–0.65)
No formal education or incomplete (4th year) 85 3 (3.5) 0.17 (0.05–0.54)
Smoking status 2311 b0.001
Never smoked 1524 246 (16.1) 1.00
Current smoker 518 153 (29.5) 2.18 (1.73–2.75)
Ex-smoker 269 48 (17.8) 1.13 (0.80–1.59)
Current smokers: length of smoking history, y 512 b0.001
1–10 385 137 (35.6) 1.00
11–20 79 11 (13.9) 0.29 (0.15–0.57)
≥21 48 5 (10.4) 0.21 (0.08–0.54)
Current smokers: no. of cigarettes smoked 518 0.380
b7 weekly 91 21 (23.1) 1.00
1–9 daily 231 68 (29.4) 1.39 (0.79–2.44)
10–20 daily 178 57 (32.0) 1.57 (0.90–2.81)
>20 daily 18 7 (38.9) 2.12 (0.73–6.16)
Age at ﬁrst sexual intercourse, y 948 b0.001
≥25 30 4 (13.3) 1.00
21–24 113 15 (13.3) 1.00 (0.30–3.25)
19–20 162 39 (24.1) 2.06 (0.68–6.27)
17–18 351 89 (25.4) 2.21 (0.75–6.50)
15–16 230 64 (27.8) 2.51 (0.84–7.46)
≤14 62 25 (40.3) 4.39 (1.37–14.13)
Prior pregnancies 2326 b0.001
Yes 1277 194 (15.2) 1.00
No 1049 257 (24.5) 1.81 (1.47–2.23)
Contraceptive use 2322 0.001
No 250 27 (10.8) 1.00
Yes 2072 423 (20.4) 2.12 (1.40–3.20)
Type of contraceptive
Oral contraceptive 1778 377 (21.2) 1.45 (1.04–2.03)
Intrauterine device 203 23 (11.3) 0.47 (0.30–0.73)
Condom 618 133 (21.5) 1.10 (0.87–1.39)
Tubal ligation 102 6 (5.9) 0.23 (0.10–0.54)
Other method 63 3 (4.8) 0.19 (0.06–0.61)
Lifetime number of sexual partners 2287 b0.001
1 1333 131 (9.8) 1.00
2–4 834 257 (30.8) 4.09 (3.24–5.16)
5–10 120 58 (48.3) 8.58 (5.75–12.82)
Any circumcised sexual partner 2166 0.001
No 1928 351 (18.2) 1.00
Yes 238 66 (27.7) 1.72 (1.27–2.34)
Any sexually transmitted disease in the past 12 mo 2304 b0.001
Yes 58 25 (43.1) 1.00
No 2246 426 (19.0) 0.31 (0.18–0.53)
Retroviral disease 58 b0.001
Yes 7 1 (14.3) 1.00
No 51 24 (47.1) 5.33 (0.60–47.52)
Herpes 58 b0.001
Yes 7 3 (42.9) 1.00
No 51 22 (43.1) 1.01 (0.21–4.99)
Genital warts 58 b0.001
Yes 20 10 (50.0) 1.00
No 38 15 (39.5) 0.65 (0.22–1.94)
Hepatitis 58 b0.001
Yes 4 3 (75.0) 1.00
No 54 22 (40.7) 0.23 (0.02–2.35)
Other sexually transmitted disease 58 b0.001
Yes 23 11 (47.8) 1.00
No 35 14 (40.0) 0.73 (0.25–2.10)
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Table 1 (continued)
Explanatory variable No. of participants HPV positive (any genotype) a OR (95% CI) b P value
History of cervical intraepithelial neoplasia 2298 0.878
No 2234 436 (19.5) 1.00
Yes 64 12 (18.8) 0.95 (0.50–1.80)
Currently immunocompromised 2305 0.849
Yes 28 5 (17.9) 1.00
No 2277 441 (19.4) 1.11 (0.42–2.92)
Abbreviations: CI, conﬁdence interval; HPV, human papillomavirus; OR, odds ratio.
a Values are given as number (percentage).
b An OR of 1.00 represents the null hypothesis of no association.
115A. Pista et al. / International Journal of Gynecology and Obstetrics 118 (2012) 112–116lower risk of HPV infection than women who had smoked for up to
10 years. Among women who had smoked for 11–20 years, the OR
was 0.42 (95% CI, 0.20–0.87; P=0.019), whereas the OR for women
who had smoked for 21 years or more was 0.50 (95% CI, 0.18–1.41;
not signiﬁcant). A high lifetime number of sexual partners remained
a signiﬁcant predictor of HPV infection, with more than a 5-fold
increased risk in women with 5–10 sexual partners compared with
women reporting 1 lifetime sexual partner. The OR for this associa-
tion was 5.44 (95% CI, 3.51–8.43; Pb0.001). Women reporting any
STD in the past 12 months showed an increased risk of HPV infectionTable 2
Multivariate logistic regression analysis between HPV infection (any genotype) and the
explanatory variables.a
Explanatory variable No. of
participants
OR (95% CI) b P value
Age, y 2295 b0.001
60–64 192 1.00
50–59 221 0.96 (0.42–2.23)
40–49 215 1.36 (0.62–2.97)
30–39 252 1.46 (0.69–3.10)
25–29 456 2.32 (1.15–4.67)
20–24 686 3.02 (1.52–6.00)
18–19 273 2.50 (1.22–5.13)
Country of birth 2295 0.002
Portugal 2179 1.00
Other 116 2.00 (1.30–3.06)
















of smoking history, y
510 0.004
1–10 384 1.00
11–20 78 0.42 (0.20–0.87)





2–4 828 3.10 (2.42–3.97)
5–10 120 5.44 (3.51–8.43)
Any sexually transmitted




Yes 58 1.79 (1.00–3.23)
Abbreviations: CI, conﬁdence interval; HPV, human papillomavirus; OR, odds ratio.
a The multivariate logistic regression analysis was adjusted for age group and
Regional Health Administration. Explanatory variables were identiﬁed as statistically
signiﬁcant (Pb0.05) in the univariate analysis.
b An OR of 1.00 represents the null hypothesis of no association. Model evaluation:
P=0.368 (Hosmer and Lemeshow test); Pb0.001 (omnibus test of model coefﬁcients);
Nagelkerke R2=0.205.(OR 1.79; 95% CI 1.00–3.23) and this observation bordered on statis-
tical signiﬁcance (P=0.052).
4. Discussion
A risk factor analysis was carried out as part of the CLEOPATRE
Portugal study, a population-based study that aims to evaluate the
prevalence of cervical HPV infection among women living in main-
land Portugal [10]. The present study evaluated a range of demo-
graphic, socioeconomic, lifestyle, and medical variables for their
potential to predict the likelihood of HPV infection. The variables
identiﬁed as risk factors for HPV infection were young age; country
of birth other than Portugal; secondary level of education; a smoking
history of up to 10 years; a high lifetime number of sexual partners;
and any STD in the last 12 months.
The risk of HPV infection was highest among women aged
20–24 years but declined with increasing age. The identiﬁcation of
age as a signiﬁcant predictor of HPV infection was expected, as it is
well recognized that young adults have an increased risk of acquiring
HPV, and that HPV prevalence decreases with age [12–14]. In Latin
American countries, a second peak of HPV prevalence has been
detected among older age groups (≥45 years) [15,16]. In agreement
with other European data [12,16], no second prevalence peak was
observed in the present study [10].
Lifetime number of sexual partners was identiﬁed as a strong
determinant of HPV infection in the multivariate analysis. Women
reporting 5–10 sexual partners had a 5.44-fold higher risk of infection
than women reporting 1 partner. This observation is consistent
with the ﬁndings of an Italian study conducted in women aged
18–24 years, which showed that women with 5 or more sexual part-
ners in the previous 3 years had a 6.8-fold increased risk of infection
compared with women with 1 partner [17].
In terms of smoking habits, there was an apparent protective
effect among women who had been smoking for more than 10 years
compared with women who had been smoking for a shorter period
of time. The number of cigarettes smoked each day or week did not
affect the risk of HPV infection in the multivariate analysis. These
ﬁndings differ from those of other studies that have examined the re-
lationship between smoking and HPV infection. The study in young
women in Italy [17] demonstrated a 2-fold higher risk of infection
among women smoking more than 10 cigarettes per day compared
with non-smokers. Similarly, after adjusting for the lifetime number
of sexual partners in a pooled analysis by the International Agency
for Research on Cancer (IARC), the risk of HPV infection increased
with smoking intensity [9]. The increased prevalence of HPV infection
observed in women with a shorter versus a longer smoking history in
the present study would suggest that the effects of age may be over-
riding the effects of smoking.
Compared with women born in mainland Portugal, the risk of HPV
infection was doubled among women born elsewhere. The most
frequent countries of birth other than Portugal, in descending order,
were Portuguese-speaking African countries, Brazil, and eastern
European countries. This ﬁnding might be related to the fact that
the adjusted HPV prevalence is high in these regions [15].
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infection revealed that women educated up to secondary school level
had the highest risk of infection. In an analysis of data from 2 large
multicenter IARC studies, no association between education level
and HPV infection emerged [18]. Education level alone is an inade-
quate measure of socioeconomic status, which is inﬂuenced by a
combination of other factors. In the IARC analysis [18], an increase
in the incidence of cervical cancer among women of low socioeco-
nomic status was attributed largely to age at ﬁrst sexual intercourse,
age at ﬁrst pregnancy, and parity. The association between secondary
level education and HPV infection observed in the present study is
probably related to age, with younger women being more likely to
report attainment of secondary level education.
As for similar studies, there are some potential limitations and a risk
of data bias in the present study, particularly in relation to the explana-
tory variables “age at ﬁrst sexual intercourse,” “lifetime number of
sexual partners,” and “any circumcised sexual partner.” These variables
cover aspects of sexual behavior that women may feel sensitive about,
or be uninformed about, and the responses to these questions may
not have been answered accurately by some women. Data collection
for the variable “age at ﬁrst sexual intercourse” was introduced after
the study had already started, and therefore early study entrants were
not questioned on this variable. Although this variable was statistically
signiﬁcant in the univariate model, it was excluded from the multivari-
ate analysis because the number of responses was low. The questions
relating to “any circumcised sexual partner” (small number of cases to
draw conclusions) and “contraceptive use” were considered to have
been formulated inadequately. As a consequence, the risks associated
with these variables should be interpreted with caution.
In conclusion, the CLEOPATRE Portugal study has identiﬁed a num-
ber of demographic, socioeconomic, lifestyle, and medical factors that
may help predict cervical HPV infection among women in Portugal.
Lifetime number of sexual partners was identiﬁed as a major risk fac-
tor for HPV infection. Other notable risk factors were birth in countries
other than mainland Portugal and a history of any STD in the past
12 months. These data will contribute to a better understanding of
thewide spectrumof HPV infection across Europe, andmay contribute
to the identiﬁcation of women at increased risk of HPV infection.
Acknowledgments
The study was sponsored by Sanoﬁ Pasteur.
Conﬂict of interest
The National Institute of Health (INSA), the sponsor, and the
CLEOPATRE Portugal study coordinators were involved in the study
design, database analysis, and preparation and review of the
manuscript. A.P. received a travel grant from Sanoﬁ Pasteur MSD-
Portugal; C.F. de O. received a travel grant and hotel expenses from
Sanoﬁ Pasteur MSD-Portugal; M.J.C. is an employee in the Medical
Department of Sanoﬁ Pasteur MSD-Portugal; M.T.P. has acted as an
advisory board member for Sanoﬁ Pasteur MSD-Portugal.References
[1] Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al.
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.
J Pathol 1999;189(1):12–9.
[2] Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papilloma-
virus type distribution in invasive cervical cancer and high-grade cervical lesions:
a meta-analysis update. Int J Cancer 2007;121(3):621–32.
[3] von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J
Dermatol 2001;11(6):598–603.
[4] Ammatuna P, Giovannelli L, Matranga D, Ciriminna S, Perino A. Prevalence of
genital human papilloma virus infection and genotypes among young women in
Sicily, South Italy. Cancer Epidemiol Biomarkers Prev 2008;17(8):2002–6.
[5] Karlsson R, Jonsson M, Edlund K, Evander M, Gustavsson A, Bodén E, et al. Lifetime
number of partners as the only independent risk factor for human papillomavirus
infection: a population-based study. Sex Transm Dis 1995;22(2):119–27.
[6] Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJ, Clifford GM, et al.
Sexual behavior, condom use, and human papillomavirus: pooled analysis of the
IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers
Prev 2006;15(2):326–33.
[7] Muñoz N, Kato I, Bosch FX, Eluf-Neto J, De Sanjosé S, Ascunce N, et al. Risk factors
for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23(6):
504–10.
[8] Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, et al. Reproductive
factors, oral contraceptive use, and human papillomavirus infection: pooled anal-
ysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev
2006;15(11):2148–53.
[9] Vaccarella S, Herrero R, Snijders PJ, Dai M, Thomas JO, Hieu NT, et al. Smoking and
human papillomavirus infection: pooled analysis of the International Agency for
Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008;37(3):536–46.
[10] Pista A, de Oliveira CF, Cunha MJ, Paixao MT, Real O, CLEOPATRE Portugal Study
Group. Prevalence of human papillomavirus infection in women in Portugal: the
CLEOPATRE Portugal study. Int J Gynecol Cancer 2011;21(6):1150–8.
[11] Grechanovsky E, Pinsker I. Conditional p-values for the F-statistic in a forward
selection procedure. Comput Stat Data Anal 1995;20(3):239–63.
[12] Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based
prevalence, type- and age-speciﬁc distribution of HPV in women before introduc-
tion of an HPV-vaccination program in Denmark. Int J Cancer 2008;123(8):
1864–70.
[13] Ronco G, Ghisetti V, Segnan N, Snijders PJ, Gillio-Tos A, Meijer CJ, et al. Prevalence
of human papillomavirus infection in women in Turin, Italy. Eur J Cancer
2005;41(2):297–305.
[14] Uusküla A, Kals M, Kosenkranius L, McNutt LA, DeHovitz JJ. Population-based
type-speciﬁc prevalence of high-risk human papillomavirus infection in Estonia.
BMC Infect Dis 2010;10:63.
[15] de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. World-
wide prevalence and genotype distribution of cervical human papillomavirus
DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis
2007;7(7):453–9.
[16] Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations
in the age-speciﬁc curves of human papillomavirus prevalence in women world-
wide. Int J Cancer 2006;119(11):2677–84.
[17] Confortini M, Carozzi F, Zappa M, Ventura L, Iossa A, Cariaggi P, et al. Human
papillomavirus infection and risk factors in a cohort of Tuscan women aged 18-24:
results at recruitment. BMC Infect Dis 2010;10:157.
[18] Franceschi S, PlummerM, Clifford G, de Sanjose S, Bosch X, Herrero R, et al. Differences
in the risk of cervical cancer and human papillomavirus infection by education level.
Br J Cancer 2009;101(5):865–70.
